S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?

Intercept Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ICPT)

$19.00
+0.04 (+0.21%)
(As of 11/8/2023)
Compare
Today's Range
$18.98
$19.01
50-Day Range
$18.20
$19.00
52-Week Range
$8.82
$21.86
Volume
3.96 million shs
Average Volume
1.36 million shs
Market Capitalization
$794.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.18

Intercept Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
22.0% Upside
$23.18 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
0.00mentions of Intercept Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to $1.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

892nd out of 952 stocks

Biotechnology Industry

26th out of 33 stocks


ICPT stock logo

About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

ICPT Stock Price History

ICPT Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?
Alfasigma To Acquire Intercept Pharma Fo $19 Per Share In Cash
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
341
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.18
High Stock Price Target
$54.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+22.0%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$221.82 million
Pretax Margin
-18.09%

Debt

Sales & Book Value

Annual Sales
$285.71 million
Book Value
$1.72 per share

Miscellaneous

Free Float
39,192,000
Market Cap
$794.77 million
Optionable
Optionable
Beta
0.88
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Jerome B. Durso (Age 55)
    President, CEO & Director
    Comp: $1.37M
  • Mr. Andrew Saik (Age 54)
    Chief Financial Officer
    Comp: $888.6k
  • Mr. Jared M. Freedberg J.D. (Age 55)
    General Counsel
    Comp: $812.55k
  • Ms. Linda M. Richardson (Age 59)
    Executive VP & Chief Commercial Officer
    Comp: $837.73k
  • Dr. M. Michelle Berrey M.D. (Age 56)
    M.P.H., President of Research & Development and Chief Medical Officer
    Comp: $1.12M
  • Mr. Rocco Venezia (Age 47)
    Chief Accounting Officer & Treasurer
    Comp: $660.62k
  • Mr. Nareg Sagherian
    Executive Director of Global Investor Relations
  • Mr. David Ford (Age 53)
    Chief Human Resources Officer
    Comp: $434.9k
  • Dr. Mark Pruzanski M.D. (Age 55)
    Founder, Advisor & Director
    Comp: $1.3M
  • Paul Nitschmann
    Senior Vice President of Regulatory Affairs














ICPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings
or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price target for 2024?

8 analysts have issued 1 year price objectives for Intercept Pharmaceuticals' stock. Their ICPT share price targets range from $14.00 to $54.00. On average, they expect the company's share price to reach $23.18 in the next year. This suggests a possible upside of 22.0% from the stock's current price.
View analysts price targets for ICPT
or view top-rated stocks among Wall Street analysts.

How have ICPT shares performed in 2023?

Intercept Pharmaceuticals' stock was trading at $12.37 at the start of the year. Since then, ICPT shares have increased by 53.6% and is now trading at $19.00.
View the best growth stocks for 2023 here
.

When is Intercept Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our ICPT earnings forecast
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.20. The biopharmaceutical company had revenue of $88.79 million for the quarter, compared to the consensus estimate of $88.02 million. Intercept Pharmaceuticals had a negative net margin of 19.39% and a negative trailing twelve-month return on equity of 77.48%.

What ETF holds Intercept Pharmaceuticals' stock ?

Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Alpine Associates Management Inc. (5.27%), Hsbc Holdings PLC (1.09%), Acadian Asset Management LLC (0.98%), Northern Trust Corp (0.92%), Versor Investments LP (0.91%) and Rafferty Asset Management LLC (0.73%). Insiders that own company stock include Sandip Kapadia and Srinivas Akkaraju.
View institutional ownership trends
.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ICPT) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -